{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T22:33:06Z","timestamp":1766788386696,"version":"3.44.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ijtb.2021.07.018","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T04:01:30Z","timestamp":1628222490000},"page":"470-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spectrum of anti tubercular therapy induced cutaneous adverse drug reactions and its management through rechallenge: A prospective study at a Tertiary Care Centre"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-2466","authenticated-orcid":false,"given":"Bina","family":"Modi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Modha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2021.07.018_bib1","unstructured":"World Health Organization. Global Tuberculosis Report 2019. Introduction. Available from: https:\/\/www.who.int\/tb\/publications\/global_report\/gtbr2019."},{"year":"2020","series-title":"National TB elimination programme annual report","key":"10.1016\/j.ijtb.2021.07.018_bib2"},{"issue":"5","key":"10.1016\/j.ijtb.2021.07.018_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21315\/mjms2018.25.5.10","article-title":"Evaluation of adverse reactions induced by anti-tuberculosis drugs in Hospital Pulau Pinang","volume":"25","year":"2018","journal-title":"Malays J Med Sci"},{"issue":"2","key":"10.1016\/j.ijtb.2021.07.018_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/idoj.IDOJ_133_19","article-title":"Spectrum of cutaneous adverse drug reactions to anti-tubercular drugs and safe therapy after re-challenge - a retrospective study","volume":"11","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.ijtb.2021.07.018_bib5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1034\/j.1398-9995.2003.00279.x","article-title":"Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations","volume":"58","author":"Aberer","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.ijtb.2021.07.018_bib6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ijtb.2021.07.018_bib7","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0190-9622(85)70156-9","article-title":"Cutaneous drug reactions: Pathogenesis and clinical classification","volume":"13","author":"Wintroub","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijtb.2021.07.018_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1590\/S1806-37132015000100010","article-title":"Risk factors associated with adverse reactions to ant tuberculosis drugs","volume":"41","author":"Resende","year":"2015","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.ijtb.2021.07.018_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","article-title":"Factors affecting the development of adverse drug reactions","volume":"22","author":"Alomar","year":"2014","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.ijtb.2021.07.018_bib10","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.18203\/2320-6012.ijrms20163312","article-title":"Profile of adverse drug reactions in patients on anti-tubercular drugs in a sub Himalayan rural tertiary care teaching hospital","volume":"4","author":"Sood","year":"2016","journal-title":"Int J Res Med Sci"},{"key":"10.1016\/j.ijtb.2021.07.018_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00409-2017","article-title":"Can toxicities induced by anti-tuberculosis drugs be better managed in diabetic patients?","volume":"50","author":"Yew","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2021.07.018_bib12","first-page":"144","article-title":"Incidence and risk factors of major toxicity associated to first-line anti tuberculosis drugs for latent and active tuberculosis during a period of 10 years","volume":"21","author":"Castro","year":"2015","journal-title":"Rev Port Pneumol"},{"key":"10.1016\/j.ijtb.2021.07.018_bib13","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from 1st line anti-tuberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijtb.2021.07.018_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5415\/apallergy.2014.4.3.156","article-title":"A retrospective study on sequential desensitization-Rechallenge for antituberculosis drug allergy","volume":"4","author":"Thong","year":"2014","journal-title":"Asia Pacific allergy"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570721001396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570721001396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T04:00:35Z","timestamp":1758081635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570721001396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0019570721001396"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2021.07.018","relation":{},"ISSN":["0019-5707"],"issn-type":[{"type":"print","value":"0019-5707"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spectrum of anti tubercular therapy induced cutaneous adverse drug reactions and its management through rechallenge: A prospective study at a Tertiary Care Centre","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2021.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}